BioSpace News Archive

Covalon Technologies Ltd. today announced an expert-led webinar titled “Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention” will be held on Thursday, June 22, 2023 at 1pm ET.

BioVie Inc. today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study ( NCT04669028 ) of NE3107 in patients with mild to moderate Alzheimer’s disease will be presented.

Crescita Therapeutics Inc. today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023 for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly.

Ocuphire Pharma, Inc. today announced that Victor H. Gonzalez, MD will present a late breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy at the 83rd Scientific Sessions of the American Diabetes Association (ADA), in San Diego, CA, June 23-26.

Cognizant announced that it is partnering with Accuray Incorporated to support the company’s deployment of SAP S/4HANA to obtain better data and analytics, and achieve greater business efficiencies.

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ subscription service on the genetics of panic attacks, or episodes of intense anxiety with symptoms that include hyperventilation and a racing heart.

Noema Pharma today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.

Anumana, Inc has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the early identification of cardiac amyloidosis, a life-threatening, rare, underdiagnosed cause of heart failure.

Alterity Therapeutics today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, 22 June 2023 at 10:30 a.m. AFST.